NANOBIOTIX (EGFF)
Sector: Hospital • Location: France
Source: European Investment Bank (EIB)
Financing the Borrower's planned expenditures in Research, Development and Innovation (RDI). The RDI expenditure programme will include the activities required to bring NBTXR3 (a nanoparticle radio-enhancer product) to the market, this will include the design and conduct of clinical trials. The development programme primarily targets indications in Soft Tissue Sarcomas, Head and Neck tumours and o
- Status
- Prospective
- Sector
- Hospital, Hotel, Manufacturing (Industrial), Government
- Location
- France
- Updated
- 19 Nov 2026
- Source
- European Investment Bank (EIB)
ConstructChat
Ask ConstructChat about NANOBIOTIX (EGFF)
Pick a question to edit it, or write your own.
First answer free · no account
Project Information FAQ
Project Information
Participants
Sponsoring Agency |
Status
Original status | financed |
Taiyo status | Prospective |
Taiyo last update | 2026-11-19 |
Contact
| Not available for this record. |
Description
Description | Financing the Borrower's planned expenditures in Research, Development and Innovation (RDI). The RDI expenditure programme will include the activities required to bring NBTXR3 (a nanoparticle radio-enhancer product) to the market, this will include the design and conduct of clinical trials. The development programme primarily targets indications in Soft Tissue Sarcomas, Head and Neck tumours and other solid tumours. |
Original sector | Services |
Budget |
Location
Country | France |
Source
Source reliability | High |
Source | European Investment Bank (EIB) |
URL |
More Details
Record type | Project |
Sector | Hospital, Hotel, Manufacturing (Industrial), Government |
Article published date | 2023-05-08 |
Research
Free account
View all details
You are reading the public part. A free account opens the rest:
- Every detail on this project
- News and media coverage
- Technical research
Free account · no card · lands you back on this project
